Clinical trials
-
NSCLC – MET high with MYTX-011 ADC
Read more: NSCLC – MET high with MYTX-011 ADCA Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer
-
Lung Cancer – EGFR mutation – 2nd line or more
Read more: Lung Cancer – EGFR mutation – 2nd line or moreA Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics, and Antitumor Activity of a Chimeric Degradation Activating Compound (CDAC) Degrading Epidermal Growth Factor Receptor (EGFR), BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
-
Solid Tumours – TransCon IL-2 β/γ Alone or in Combo with Pembrolizumab or Standard of Care Chemotherapy
Read more: Solid Tumours – TransCon IL-2 β/γ Alone or in Combo with Pembrolizumab or Standard of Care ChemotherapyA Study to Investigate Safety and Tolerability of TransCon IL-2 β/ γ Alone or in Combination With Pembrolizumab and/ or Chemotherapy or TransCon TLR7/ 8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumour Malignancies (ASCENDIS)
-
Lung Cancer 1st line KRAS G12C PDL1 neg
Read more: Lung Cancer 1st line KRAS G12C PDL1 negA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
-
Ovarian – Platinum Resistant
Read more: Ovarian – Platinum ResistantThis is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
-
Lung Cancer PD-L1 <50% 1st line met
Read more: Lung Cancer PD-L1 <50% 1st line metThis study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
-
Breast ER+/HER2- 2nd line met
Read more: Breast ER+/HER2- 2nd line metThis phase 3 clinical study compares the safety and efficacy of OP-1250 to the standard of care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on at least one endocrine therapy in combination with a CDK4/6 inhibitor.
-
Lung Cancer PD-L1 ≥50% 1st line met
Read more: Lung Cancer PD-L1 ≥50% 1st line met